C5aRAD

C-terminal truncated, cysteine-terminated, dimeric derivative of complement 5a; amino acid sequence in first source

Also Known As:

C5a receptor antagonist (C5a1-71T1M,C27S,Q71C) dimer; CGS 32359; CGS-32359

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Infarction (Infarctions) 08/01/2000 - "This study tested the hypothesis that a recombinant human C5a antagonist, CGS 32359, attenuates neutrophil activation and reduces infarct size in a porcine model of surgical revascularization. "
2.	Coronary Occlusion 08/01/2000 - "We conclude that the recombinant human C5a receptor antagonist CGS 32359 inhibits surgical ischemia-reperfusion injury after coronary occlusion."
3.	Reperfusion Injury 08/01/2000 - "We conclude that the recombinant human C5a receptor antagonist CGS 32359 inhibits surgical ischemia-reperfusion injury after coronary occlusion."
4.	Neutropenia 06/01/1998 - "Furthermore, a 5-mg/kg i.v. bolus of C5aRAD significantly inhibited C5a-induced neutropenia in micropigs when challenged with C5a 30 min after C5aRAD administration. "

1.	Anaphylatoxin C5a Receptor